Reported Sunday, Opthea Successfully Completes A$55.9M Retail Entitlement Offer, Marking The Final Stage Of A$227.3M Capital Raising

7/15/24 2:07:52 AM ET

$OPT

Biotechnology: Biological Products (No Diagnostic Substances)

Health Care

Get the next $OPT alert in real time by email

New Shares under the Retail Entitlement Offer and New Options under the Placement and Entitlement Offer expected to commence normal trading on Thursday, 18 July 2024
Retail Entitlement Offer follows successful Institutional Entitlement Offer and institutional Placement raising approximately A$171.5m (US$113.2m1)
Completion of Retail Entitlement Offer represents final stage of Opthea's approximately A$227.3m (US$150.0m1) capital raising

Get the next $OPT alert in real time by email

Crush Q1 2026 with the Best AI Superconnector

Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

AI-Powered Inbox

Context-aware email replies

Strategic Decision Support

Get Started with Standout.work

Recent Analyst Ratings for
$OPT

Date	Price Target	Rating	Analyst
3/25/2025	$2.00	Buy → Neutral	H.C. Wainwright
3/25/2025	$12.00 → $1.00	Outperform → Market Perform	Leerink Partners
3/25/2025	$8.00 → $1.00	Buy → Underperform	Jefferies
3/24/2025		Outperform → Perform	Oppenheimer
12/8/2022	$14.00	Buy	H.C. Wainwright
4/26/2022	$25.00	Outperform	SVB Leerink

More analyst ratings

$OPT
Press Releases

Fastest customizable press release news feed in the world

View All

Opthea Provides Corporate Update

Successful DFA settlement reached Company with cash and cash equivalents of approximately USD20M Dr Fred Guerard, CEO, Tom Reilly, CFO, and Sujal Shah, Director, to step down Dr Jeremy Levin to continue as Chairman and to assume additional responsibilities as of September 1st MELBOURNE, Australia and PRINCETON, N.J., Aug. 18, 2025 (GLOBE NEWSWIRE) -- Opthea Limited (NASDAQ:OPT, "Opthea", the "Company")), today provided a corporate update following the successful settlement of the Development Funding Agreement ("DFA") with the two investors under the DFA. DFA Settlement In March of 2025, after the primary endpoints were not met in both COAST and ShORe phase 3 clinical trials, Opthea

8/18/25 7:00:00 PM ET

$OPT

Biotechnology: Biological Products (No Diagnostic Substances)

Health Care

Opthea Announces Decision to Discontinue Wet AMD Trials

ShORe Phase 3 topline results accelerated; trial did not meet primary endpoint of mean change in BCVA from baseline to week 52 Opthea and DFA Investors agreed to terminate both COAST and ShORe trials Opthea continues to consider impact of negative trial results under its Development Funding Agreement (DFA) and on the Company as a going concern MELBOURNE, Australia and PRINCETON, N.J., March 31, 2025 (GLOBE NEWSWIRE) -- Opthea Limited (NASDAQ:OPT, "Opthea", the "Company")), a clinical-stage biopharmaceutical company developing novel therapies to treat highly prevalent and progressive retinal diseases, including wet age-related macular degeneration (wet AMD), today announced updates on i

3/31/25 12:01:00 AM ET

$OPT

Biotechnology: Biological Products (No Diagnostic Substances)

Health Care

Opthea Announces COAST Phase 3 Trial Topline Results

COAST Phase 3 trial failed to meet primary endpoint of mean change in BCVA from baseline to week 52 Opthea considering impact of negative trial results under its Development Funding Agreement and on the Company as a going concern MELBOURNE, Australia and PRINCETON, N.J., March 24, 2025 (GLOBE NEWSWIRE) -- Opthea Limited (NASDAQ:OPT, "Opthea", the "Company")), a clinical-stage biopharmaceutical company developing novel therapies to treat highly prevalent and progressive retinal diseases, including wet age-related macular degeneration (wet AMD), today announced results from its global Phase 3 clinical trial COAST (Combination OPT-302 with Aflibercept Study) in patients with wet AMD

3/24/25 12:01:00 AM ET

$OPT

Biotechnology: Biological Products (No Diagnostic Substances)

Health Care

$OPT
Leadership Updates

Live Leadership Updates

View All

Opthea Appoints Kathy Connell to Board of Directors

Ms. Connell is a commercial executive with business development expertise Appointment takes place as Opthea prepares for Phase 3 wet AMD topline data in 2025 MELBOURNE, Australia, and PRINCETON, N.J., Nov. 15, 2024 (GLOBE NEWSWIRE) -- Opthea Limited (NASDAQ:OPT, "Opthea", the "Company")), a clinical-stage biopharmaceutical company developing novel therapies to treat highly prevalent and progressive retinal diseases, including wet age-related macular degeneration (wet AMD), today announced the appointment of Kathy Connell, GAICD, to the Board of Directors (the "Board") as a Non-Executive Director. Ms. Connell's appointment was effective immediately after the Annual General Meeting of the

11/15/24 7:00:48 AM ET

$OPT

Biotechnology: Biological Products (No Diagnostic Substances)

Health Care

Opthea Appoints Chief Medical Officer and Chief Financial Officer as Company Prepares for Phase 3 Topline Data Readouts in 2025

Parisa Zamiri, MD, PhD, and Tom Reilly respectively appointed CMO and CFO Anand Sundaram appointed Vice President Marketing MELBOURNE, Australia and PRINCETON, N.J., Oct. 08, 2024 (GLOBE NEWSWIRE) -- Opthea Limited (NASDAQ:OPT, "Opthea", the "Company"))), a clinical-stage biopharmaceutical company developing novel therapies to treat highly prevalent and progressive retinal diseases, including wet age-related macular degeneration (wet AMD), today announced three senior hires as the Company continues to prepare for the sozinibercept Phase 3 topline data readouts of COAST anticipated in early Q2 calendar year 2025 and ShORe in mid calendar year 2025. "Opthea is at an inflection point with

10/8/24 7:00:00 AM ET

$OPT

Biotechnology: Biological Products (No Diagnostic Substances)

Health Care

Opthea Welcomes International Retina Thought Leaders to Join Its Medical Advisory Board

MELBOURNE, Australia and PRINCETON, N.J., July 17, 2024 (GLOBE NEWSWIRE) -- Opthea Limited (NASDAQ:OPT, "Opthea", the "Company"))), a clinical-stage biopharmaceutical company developing novel therapies to treat highly prevalent and progressive retinal diseases, including wet age-related macular degeneration (wet AMD), today announces the formation of its Medical Advisory Board ("MAB") composed of 10 retina thought leaders from countries around the world including the US, Argentina, Australia, China, France, Germany, and Israel. Chaired by Arshad M. Khanani, MD, MA, FASRS, Chief Medical Advisor of Opthea, the MAB's role is to advise the Company on opportunities to address the unmet medical

7/17/24 7:15:00 AM ET

$OPT

Biotechnology: Biological Products (No Diagnostic Substances)

Health Care

Reported Sunday, Opthea Successfully Completes A$55.9M Retail Entitlement Offer, Marking The Final Stage Of A$227.3M Capital Raising

Crush Q1 2026 with the Best AI Superconnector

Recent Analyst Ratings for
$OPT

Reported Sunday, Opthea Successfully Completes A$55.9M Retail Entitlement Offer, Marking The Final Stage Of A$227.3M Capital Raising

Crush Q1 2026 with the Best AI Superconnector

Recent Analyst Ratings for
$OPT

$OPT
Press Releases

Opthea Provides Corporate Update

Opthea Announces Decision to Discontinue Wet AMD Trials

Opthea Announces COAST Phase 3 Trial Topline Results

$OPT
SEC Filings

SEC Form 15F-12B filed by Opthea Limited

SEC Form 6-K filed by Opthea Limited

SEC Form 6-K filed by Opthea Limited

$OPT
Analyst Ratings

Opthea Ltd. downgraded by H.C. Wainwright with a new price target

Opthea Ltd. downgraded by Leerink Partners with a new price target

Opthea Ltd. downgraded by Jefferies with a new price target

$OPT
Leadership Updates

Opthea Appoints Kathy Connell to Board of Directors

Opthea Appoints Chief Medical Officer and Chief Financial Officer as Company Prepares for Phase 3 Topline Data Readouts in 2025

Opthea Welcomes International Retina Thought Leaders to Join Its Medical Advisory Board

$OPT
Large Ownership Changes

Amendment: SEC Form SC 13G/A filed by Opthea Limited

Amendment: SEC Form SC 13G/A filed by Opthea Limited

SEC Form SC 13G/A filed by Opthea Limited (Amendment)

$OPT
Financials

Opthea Announce MST Access Hosted Conference Call with Professor Jason S. Slakter, MD

Reported Sunday, Opthea Successfully Completes A$55.9M Retail Entitlement Offer, Marking The Final Stage Of A$227.3M Capital Raising

Crush Q1 2026 with the Best AI Superconnector

Recent Analyst Ratings for $OPT

Reported Sunday, Opthea Successfully Completes A$55.9M Retail Entitlement Offer, Marking The Final Stage Of A$227.3M Capital Raising

Crush Q1 2026 with the Best AI Superconnector

Recent Analyst Ratings for $OPT

$OPT Press Releases

Opthea Provides Corporate Update

Opthea Announces Decision to Discontinue Wet AMD Trials

Opthea Announces COAST Phase 3 Trial Topline Results

$OPT SEC Filings

SEC Form 15F-12B filed by Opthea Limited

SEC Form 6-K filed by Opthea Limited

SEC Form 6-K filed by Opthea Limited

$OPT Analyst Ratings

Opthea Ltd. downgraded by H.C. Wainwright with a new price target

Opthea Ltd. downgraded by Leerink Partners with a new price target

Opthea Ltd. downgraded by Jefferies with a new price target

$OPT Leadership Updates

Opthea Appoints Kathy Connell to Board of Directors

Opthea Appoints Chief Medical Officer and Chief Financial Officer as Company Prepares for Phase 3 Topline Data Readouts in 2025

Opthea Welcomes International Retina Thought Leaders to Join Its Medical Advisory Board

$OPT Large Ownership Changes

Amendment: SEC Form SC 13G/A filed by Opthea Limited

Amendment: SEC Form SC 13G/A filed by Opthea Limited

SEC Form SC 13G/A filed by Opthea Limited (Amendment)

$OPT Financials

Opthea Announce MST Access Hosted Conference Call with Professor Jason S. Slakter, MD

Recent Analyst Ratings for
$OPT

Recent Analyst Ratings for
$OPT

$OPT
Press Releases

$OPT
SEC Filings

$OPT
Analyst Ratings

$OPT
Leadership Updates

$OPT
Large Ownership Changes

$OPT
Financials